Tecentriq (atezolizumab) / Roche  >>  Phase 2
Welcome,         Profile    Billing    Logout  

256 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tecentriq (atezolizumab) / Roche
NEO-TIM, NCT04722575 / 2018-004841-17: Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

Active, not recruiting
2
95
Europe
Cobimetinib 20 MG Oral Tablet, Cotellic, Vemurafenib 240 Mg Oral Capsule, Zelboraf, Atezolizumab 1200 MG in 20 ML Injection, Tecentriq
Fondazione Melanoma Onlus, Clinical Research Technology S.r.l.
Melanoma
12/23
06/27
NCT05396937: Efficacy and Safety of T+A+RAD in HCC

Recruiting
2
42
RoW
Multifocal Stereotactic Radiotherapy, Atezolizumab Injection [Tecentriq], Bevacizumab
Fudan University, Roche Pharma AG
Hepatocellular Carcinoma
12/23
12/23
ATREZZO, NCT04759248 / 2020-000245-13: Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer

Recruiting
2
55
Europe
Atezolizumab + Trastuzumab + Vinorelbine
SOLTI Breast Cancer Research Group, Roche Pharma AG
Breast Cancer
12/24
01/25
MyTACTIC, NCT04632992: A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Completed
2
252
US
Entrectinib, Rozlytrek™, RG6268, RO7102122, Inavolisib, GDC-0077, RG6114, RO7113755, Alectinib, Alecensa®, RG7853, RO5424802, Ipatasertib, GDC-0068, RG7440, RO5532961, Atezolizumab, Tecentriq®, RG7446, RO5541267, Trastuzumab Emtansine, Kadcyla®, RG3502, RO5304020, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, PHESGO™, PH FDC SC, Fixed dose combination of trastuzumab and pertuzumab administered subcutaneously, RG6264, RO7198574, Tucatinib, Tukysa™, Investigator's Choice of Chemotherapy, Paclitaxel, Tiragolumab, RG6058, RO7092284, MTIG7192A, Pralsetinib, GAVRETO™, RG6396, RO7499790
Genentech, Inc.
Advanced Unresectable or Metastatic Solid Malignancy
12/23
02/24
ASPRIA, NCT04434040: Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC

Active, not recruiting
2
40
US
Atezolizumab, Tecentriq, Sacituzumab govitecan, Trodelvy, IMMU-132
Dana-Farber Cancer Institute, Genentech, Inc., Stand Up To Cancer
Breast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNA
12/25
12/27
ABC-lung, NCT04245085 / 2019-001687-30: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma

Active, not recruiting
2
95
Europe, RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Carboplatin, Paclitaxel, Pemetrexed, Alimta
ETOP IBCSG Partners Foundation, Roche Pharma AG
EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC
12/24
12/24
NCT04321330: A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma

Completed
2
34
RoW
Atezolizumab, MPDL3280A; RO5541267; Tecentriq
Hoffmann-La Roche
Carcinoma, Thymic
07/23
06/24
BTCRC-LUN19-396, NCT04367311: Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

Recruiting
2
100
US
Atezolizumab, Docetaxel, Cisplatin, Pemetrexed
Nasser Hanna, Genentech, Inc.
Lung Cancer, NSCLC
06/24
01/25
AURORA, NCT05038657: Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).

Recruiting
2
36
Europe
Atezolizumab, Treatment
University Hospital Southampton NHS Foundation Trust, Cancer Research UK, Roche Pharma AG
Squamous Cell Carcinoma, Urinary Tract Cancer
01/24
01/25
STRATUM, NCT05377034: Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients

Recruiting
2
176
RoW
SIRT-Y90 with Atezolizumab + Bevacizumab, SIRT-Y90 with Placebo (IV)
National Cancer Centre, Singapore, Hoffmann-La Roche, Sirtex Medical, Singapore Clinical Research Institute
Locally Advanced Hepatocellular Carcinoma
04/25
10/26
DETERRED, NCT02525757: MPDL3280A With Chemoradiation for Lung Cancer

Active, not recruiting
2
52
US
MPDL3280A, Carboplatin, Paraplatin, Paclitaxel, Taxol, Radiation Therapy, XRT
M.D. Anderson Cancer Center, Genentech, Inc.
Lung Cancer, Non-Small Cell Lung Cancer
01/26
01/26
BIS-Program, NCT05180006: Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy

Recruiting
2
185
Europe
Atezolizumab Injection, Bevacizumab, Pertuzumab, Trastuzumab
Gustave Roussy, Cancer Campus, Grand Paris, Hoffmann-La Roche
Breast Cancer
02/25
02/26
NCT05009069: A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

Active, not recruiting
2
58
RoW
Radiotherapy, Capecitabine, Fluorouracil, Atezolizumab, Tiragolumab
Hoffmann-La Roche
Rectal Neoplasms, Rectal Cancer
11/23
10/26
NCT03093922: A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

Active, not recruiting
2
32
US
Atezolizumab, Gemcitabine, Cisplatin
Memorial Sloan Kettering Cancer Center, Ohio State University, University of Chicago, Genentech, Inc., Targos
Urothelial Carcinoma, Locally Advanced, Unresectable
03/25
03/25
NCT05359861: Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma

Active, not recruiting
2
134
US, RoW
SRF388, Atezolizumab, Tecentriq, Bevacizumab, Avastin, Placebo
Coherus Biosciences, Inc.
Hepatocellular Carcinoma
05/25
05/26
NAUTIKA1, NCT04302025: A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer

Recruiting
2
125
US
Alectinib, Entrectinib, Vemurafenib (Enrollment closed), Cobimetinib (Enrollment closed), Pralsetinib (Enrollment closed), Atezolizumab, SBRT, Resection, Chemotherapy, Divarasib
Genentech, Inc., Blueprint Medicines Corporation
Non-small Cell Lung Cancer
12/25
03/29
SKYLINE, NCT06175390: Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer

Recruiting
2
160
Europe
68Ga-FAPI-46 PET/CT, Tumor samples analysis, Blood samples analysis: Circulating Tumor DNA
Institut Curie, Hoffmann-La Roche
Triple Negative Breast Cancer
08/26
02/29
ProTarget, NCT04341181: - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

Recruiting
2
300
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Avelumab, Bavencio, Axitinib, Inlyta, Erlotinib, Tarceva, Vemurafenib plus Cobimetinib (combination), Zelboraf plus Cotellic (combination), Trastuzumab plus Pertuzumab (combination), Herceptin plus Perjeta (combination), Trastuzumab emtansine, Kadcyla, Vismodegib, Erivedge, Niraparib, Zejula
Ulrik Lassen, Roche Pharma AG, Pfizer, GlaxoSmithKline
Cancer, Tumors, Neoplasms, Neoplasia
04/24
04/25
ABATE, NCT04289779: Study of CAbozantinib in Combination With AtezolizumaB for Muscle-Invasive BladdEr Cancer

Recruiting
2
46
US
Cabozantinib, cabometyx, Atezolizumab, Tecentriq, Cystectomy
Deepak Kilari, Exelixis, Genentech, Inc., Medical College of Wisconsin
Bladder Cancer
07/24
09/25
NCT04710498: Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma

Active, not recruiting
2
20
US
Atezolizumab, RO5541267
Stanford University, Genentech, Inc.
Cutaneous Squamous Cell Carcinoma
02/24
11/24
NCT05312671: Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Recruiting
2
63
US
Atezolizumab, Tecentriq, Carboplatin, CBDCA, Paraplatin, JM-8, NSC-241240, Cisplatin, Cis-Diaminedichloroplatinum, CDDP, Etoposide, VP-16, VePesid, VP-16-213, EPEG, epipodophyllotoxin, NSC # 141540, Cystectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Genentech, Inc.
Small Cell Neuroendocrine Carcinoma of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder
06/25
06/27
OBERTO-301, NCT05243862: Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.

Active, not recruiting
2
18
US
PolyPEPI1018, PolyPEPI1018 CRC vaccine, Atezolizumab, Tecentriq
Treos Bio Limited, Mayo Clinic, Hoffmann-La Roche
Colorectal Cancer Metastatic
06/24
06/26
TONIC-3, NCT06342037: NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: Trial

Recruiting
2
60
Europe
Tiragolumab, Atezolizumab, Tecentriq, Ipilimumab, Yervoy
The Netherlands Cancer Institute, Hoffmann-La Roche
Metastatic Breast Cancer
04/26
04/30
NCT06475209: Adebrelimab + Apatinib in SCLC Maintenance Therapy

Recruiting
2
60
RoW
Adebrelimab combined with Apatinib
Tang-Du Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd.
SCLC
12/25
12/26
NCT04958811: Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

Recruiting
2
42
US
Tiragolumab, Atezolizumab, Bevacizumab
Georgetown University, Genentech, Inc.
Non-squamous Non-small-cell Lung Cancer
12/24
12/24
VIRO-25, NCT06463665: Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's of Choice Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Not yet recruiting
2
142
NA
Olvimulogene nanivacirepvec, Olvi-Vec, GL-ONC, GLV-1h68, Platinum chemotherapy: carboplatin or cisplatin, Brand of drug is based on institutional procurement, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel
Genelux Corporation, Newsoara Biopharma Co., Ltd.
Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
02/27
07/29
ABSK-011-201, NCT05441475: A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab in HCC Patients

Recruiting
2
62
RoW
ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w
Abbisko Therapeutics Co, Ltd
Hepatocellular Carcinoma
07/24
10/24
IMperator, NCT06331598: A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)

Recruiting
2
40
Europe
Atezolizumab, Tecentriq, Tiragolumab, MTIG7192A
Hoffmann-La Roche
Solid Tumors
10/28
09/29
NCT03417544: Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Active, not recruiting
2
19
US
ATEZOLIZUMAB, Tecentriq, PERTUZUMAB, Perjeta, TRASTUZUMAB, Herceptin
Nancy Lin, MD, Genentech, Inc.
HER2-positive Metastatic Breast Cancer, Central Nervous System Metastases
05/20
12/25
VolATIL, NCT03946358: Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers

Active, not recruiting
2
47
Europe
Blood sample collection, Tumor biopsies, CT scan, Atezolizumab, anti-PD-L1, UCPVax, Vaccine
Centre Hospitalier Universitaire de Besancon, Roche Pharma AG, National Cancer Institute, France
Squamous Cell Carcinoma of the Head and Neck, Anal Canal Cancer, Cervical Cancer
09/24
10/25
NCT04356729: A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

Recruiting
2
30
US
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Mvasi
Elizabeth Buchbinder, MD, Genentech, Inc.
Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma, Unresectable Stage IV Cutaneous Melanoma
09/24
09/25
AGADIR, NCT03915678: Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

Recruiting
2
247
Europe
Association atezolizumab + BDB001 + RT, Association atezolizumab + BDB001+ RT
Institut Bergonié, Roche Pharma AG, National Cancer Institute, France, Eikon Therapeutics
Solid Tumor, Adult, Pancreatic Cancer, Virus-associated Tumors, Non Small Cell Lung Cancer, Melanoma, Bladder Cancer, Triple Negative Breast Cancer
09/24
03/26
NCT04984811: NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

Active, not recruiting
2
83
US
efineptakin alfa, NT-I7, Atezolizumab, Tecentriq
NeoImmuneTech, Roche Pharma AG
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer
09/24
03/25
The AB7 Trial, NCT04829383: A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma

Active, not recruiting
2
50
US
Atezolizumab, Tecentriq, Bevacizumab, Avastin
Howard S Hochster, Genentech, Inc., Rutgers Cancer Institute of New Jersey
Unresectable Hepatocellular Carcinoma
10/24
10/25
NCT05101629: Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy

Active, not recruiting
2
32
Europe
Pembrolizumab, Keytruda, Lenvatinib Capsules, Lenvima
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Medizinische Hochschule Hannover, Germany, Prof. Dr. Arndt Vogel, Merck Sharp & Dohme LLC
Hepatocellular Carcinoma
10/24
12/24
REGONEXT, NCT05134532: Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC

Active, not recruiting
2
40
RoW
regorafenib
CHA University, Bayer
Hepatocellular Carcinoma
10/24
10/24
NCT03821246: Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

Recruiting
2
68
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Tocilizumab, Actemra, Etrumadenant, AB928
Lawrence Fong, Genentech, Inc.
Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate Cancer
02/25
02/25
DARWIN II, NCT02314481: Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity

Active, not recruiting
2
50
Europe
MPDL3280A, Atezolizumab, Vemurafenib, Zelboraf, Alectinib, Alecensa, Trastuzumab emtansine, T-DM1, Kadcyla
University College, London, Hoffmann-La Roche
Non-small Cell Lung Cancer
05/26
05/26
NCT05681039: Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

Recruiting
2
29
US
Tiragolumab, Atezolizumab, MPDL3280A, TECENTRIQ, Standard of Care, Questionnaires, Cisplatin, Carboplatin
M.D. Anderson Cancer Center, Genentech, Inc.
Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
11/24
11/26
NCT06439485: Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion

Not yet recruiting
2
25
US
Pemigatinib, Atezolizumab, MPDL3280A, TECENTRIQ, Bevacizumab, Avastin™, Anti-VEGF monoclonal antibody, rhuMAb-VEGF
M.D. Anderson Cancer Center, Incyte Corporation
Advanced Cholangiocarcinoma, FGFR2 Fusion
02/28
02/30
NCT01898117 / 2013-001484-23: Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer

Active, not recruiting
2
304
Europe
Carbo/cyclo, Carboplatin, Cyclophosphamide, Carbo/cyclo + atezolizumab, Atezolizumab, Paclitaxel, Paclitaxel + Atezolizumab
The Netherlands Cancer Institute, Borstkanker Onderzoek Groep, Roche Pharma AG
Breast Cancer
12/24
12/30
INTEGRATE, NCT04563338: An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases

Recruiting
2
36
Canada
Atezolizumab, TECENTRIQ, Bevacizumab, AVASTIN
University Health Network, Toronto, Hoffmann-La Roche
Hepatocellular Carcinoma, Non-small Cell Lung Cancer Metastatic, Liver Metastases
12/24
12/24
NCT04751929: Abemaciclib With or Without Atezolizumab for mCRPC

Active, not recruiting
2
75
US
Abemaciclib, Verzenio, Atezolizumab, Tecentriq
Dana-Farber Cancer Institute, Eli Lilly and Company, Genentech, Inc.
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
12/24
12/25
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
2
3791
US
Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi
American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
12/24
12/25
BTCRC LUN20-462, NCT04919382: Temozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

Recruiting
2
56
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ
Dwight Owen, Genentech, Inc.
Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
12/24
12/25
ACCRU-GI-2008, NCT05168163: Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Recruiting
2
122
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Cabozantinib, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080
Academic and Community Cancer Research United, National Cancer Institute (NCI), Genentech, Inc.
Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
12/24
12/26
NCT04541173: Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Terminated
2
6
US
Y-90 TARE, Atezolizumab, Tecentriq, Bevacizumab, Avastin
Aiwu Ruth He, MD, Georgetown University, Genentech, Inc.
Hepatocellular Carcinoma
06/23
06/23
LOST-B, NCT05537402: LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC

Recruiting
2
204
US
Atezolizumab and bevacizumab, transarterial chemoembolization (TACE) or transarterial radioembolization (TARE
University of Texas Southwestern Medical Center, Genentech, Inc.
Hepatocellular Carcinoma
01/25
01/28
NCT05060003: Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

Terminated
2
7
US
Atezolizumab, Tecentriq, Tiragolumab, Signatera Assay
Washington University School of Medicine, Genentech, Inc.
Stage II Melanoma
11/23
11/23
SKYSCRAPER-11, NCT05661578 / 2022-001157-23: A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors

Recruiting
2
60
Europe, Canada, US, RoW
Tiragolumab and Atezolizumab IV FDC
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd
PD-L1-selected Solid Tumors
02/25
02/25
NCT05538091: Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Recruiting
2
48
US
Vismodegib, ERIVEDGE, Atezolizumab, Tecentriq
Ronald Buckanovich, Genentech, Inc.
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, PARP Inhibitor, Hedgehog Inhibitor
04/28
04/28
NCT05776875: Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

Recruiting
2
24
US
Atezolizumab Injection, Tecentriq, Bevacizumab, Avastin, Transarterial chemoembolization, TACE
Yale University, Genentech, Inc.
Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
03/25
08/25
NCT03767075 / 2017-005108-89: A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)

Recruiting
2
1000
Europe
Atezolizumab, Futibatinib, TAS-120, Amivantamab, JNJ-372
Vall d'Hebron Institute of Oncology, Roche Pharma AG, Iqvia Pty Ltd, Taisho Pharmaceutical Co., Ltd., Janssen, LP
Advanced Solid Tumor
05/25
11/26
ABE-LIVER, NCT05448677: Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma

Terminated
2
3
Europe
Ezurpimtrostat, Atezolizumab, Bevacizumab
University Hospital, Grenoble, Genoscience Pharma
Hepatocellular Carcinoma
03/24
03/24
Cabatezo-1, NCT05859217: A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC

Not yet recruiting
2
40
US
Cabozantinib, Cabometyx, Atezolizumab, Tecentriq
Jun Zhang, MD, PhD, Exelixis, Genentech, Inc.
Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced NSCLC
06/26
06/28
BladderSpar, NCT03697850 / 2018-001807-35: Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy

Active, not recruiting
2
79
Europe
Atezolizumab
UNICANCER, Roche Pharma AG
Bladder Cancer
06/25
02/29
Stereosarc, NCT03548428: Stereotaxic Body Irradiation of Oligometastase in Sarcoma

Recruiting
2
103
Europe
Atezolizumab, SBRT, High Dose Radiation
Centre Antoine Lacassagne, Centre Hospitalier Universitaire de Caen, Roche Pharma AG
Sarcoma, Radiosurgery
07/25
12/27
AFT-57, NCT05798663: Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

Recruiting
2
178
US
Atezolizumab, Tecentriq, L01XC32, Tiragolumab
Alliance Foundation Trials, LLC., Genentech, Inc.
NSCLC
08/25
10/27
NCT05746481: Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

Recruiting
2
35
US
Tiragolumab, RO7092284, Atezolizumab, Tecentriq, RO5541267, Pemetrexed, Alimta, Pemfexy, Carboplatin, Paraplatin
Liza Villaruz, MD, Genentech, Inc.
Non-small Cell Lung Cancer
09/25
04/27
NCT03614949: SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

Recruiting
2
26
US
Stereotactic body radiation therapy (SBRT), radiotherapy, Atezolizumab, Tecentriq®, immunotherapy
H. Lee Moffitt Cancer Center and Research Institute, Genentech, Inc.
Cervical Cancer, Cervical Cancer Recurrent, Cervical Cancer Metastatic
10/25
10/25
NCT05999812: Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

Recruiting
2
21
US
all trans Retinoic Acid, Tretinoin, ATRA, Atezolizumab, Bevacizumab
University of Texas Southwestern Medical Center, Genentech, Inc.
Colorectal Cancer
10/26
10/28
GUNS, NCT04812366: Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

Recruiting
2
315
Canada, US
Apalutamide 60mg Tab, Abiraterone Acetate 250mg, Prednisone 5mg Tab, Docetaxel, Niraparib 100mg Oral Capsule, Atezolizumab
University of British Columbia, Janssen Inc., University Health Network, Toronto
Prostate Cancer
04/26
04/26
MoST-TAP, NCT06003621: Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients

Recruiting
2
96
RoW
Tiragolumab, RO7092284, MTIG7192A, RG-6058, Anti-TIGIT, Atezolizumab, Tecentriq, MPDL3280A, RG7446, RO5541267
Omico, Hoffmann-La Roche, The George Institute for Global Health, Australia
Solid Tumor, Adult
05/26
11/28
Kirros, NCT06096779: A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis

Recruiting
2
120
US
Atezolizumab, Tecentriq, Bevacizumab, Avastin
Genentech, Inc.
Hepatocellular Carcinoma
05/26
11/26
BELIEVE, NCT05588388: Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases

Not yet recruiting
2
39
US
Bevacizumab
Kamya Sankar, Genentech, Inc., University of Michigan, VA Ann Arbor Healthcare System
Extensive-stage Small-cell Lung Cancer, Liver Metastases
09/26
09/27
ADVANCE HCC, NCT05137899: Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy

Recruiting
2
70
Canada
Neoadjuvant
Ontario Clinical Oncology Group (OCOG), Hoffmann-La Roche
Hepatocellular Carcinoma, Portal Vein Tumour Thrombosis
06/26
06/26
SAABR, NCT04262154: Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Active, not recruiting
2
28
US
Atezolizumab, Abiraterone, Prednisone, GnRH analog, Stereotactic Body Radiotherapy (SBRT), Enzalutamide, Follow up
Memorial Sloan Kettering Cancer Center, Genentech, Inc., Stand Up To Cancer
Metastatic Prostate Cancer
09/26
09/26
NCT05870800: Neoadjuvant Chemoimmunotherapy for Resectable Non-Metastatic Proficient Mismatch Repair (PMMR) Colon Cancer

Not yet recruiting
2
30
US
Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2, Neoadjuvant Chemoimmunotherapy, Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2, mFOLFOX6, Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2, CAPEOX
Baylor College of Medicine, Genentech, Inc.
Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer
09/26
01/28
CAPTIV-8, NCT04273061: Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

Recruiting
2
200
Canada
Atezolizumab, TECENTRIQ
British Columbia Cancer Agency, Hoffmann-La Roche
Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Gynecologic Cancer, Sarcoma, Unknown Primary Tumors, Head and Neck Cancer, Skin Cancer
10/26
10/26
ANTONIO, NCT05118724: Atezolizumab in Patients With MSI-h/MMR-D Stage III Colorectal Cancer Ineligible for Oxaliplatin

Recruiting
2
80
Europe
Atezolizumab, Tecentriq
AIO-Studien-gGmbH, Roche Pharma AG, Immodulon Therapeutics Ltd
Colorectal Cancer
11/26
11/26
NCT05645692 / 2022-002265-15: A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Recruiting
2
240
Europe, US, RoW
Atezolizumab, Tobemstomig, RO7247669, Tiragolumab
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd
Urothelial Cancer
12/26
12/26
NCT05733611: RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Active, not recruiting
2
4
US
RP2, RP3, atezolizumab, bevacizumab
Replimune Inc., Roche Pharma AG
Refractory Metastatic Colorectal Cancer, pMMR, MSS
01/27
03/27
NCT05733598: RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Not yet recruiting
2
60
Europe, US
RP3, atezolizumab, bevacizumab
Replimune Inc., Roche Pharma AG
Locally Advanced Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
04/27
07/27
ATEZOBLADDERPRESERVE, NCT04186013: Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer

Active, not recruiting
2
39
Europe
Atezolizumab Injection [Tecentriq], External Beam Radiation Therapy (EBRT)
Spanish Oncology Genito-Urinary Group, Roche Farma, S.A, Dynamic Science S.L.
Bladder Cancer
02/27
05/27
NCT06099418: Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

Recruiting
2
130
US
VB10.16, Atezolizumab Injection [Tecentriq], Placebo
Nykode Therapeutics ASA, Roche Pharma AG, GOG Foundation
HPV-Related Cervical Carcinoma, HPV-Related Malignancy, Cervical Cancer
05/27
05/28
DANTE, NCT03421288 / 2017-001979-23: Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness

Recruiting
2
674
Europe
Atezolizumab, TECENTRIQ, 5-Fluorouracil, 5-FU, Calciumfolinat, Leucovorin, Oxaliplatin, ELOXATIN, Docetaxel, TAXOTERE
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
05/27
12/27
TIRANUS, NCT05661188: Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma

Recruiting
2
45
Europe
Atezolizumab plus Tiraglolumab
Grupo Espanol Multidisciplinario del Cancer Digestivo, Hoffmann-La Roche
Squamous Cell Carcinoma of the Anal Canal
06/27
06/28
NCT03708224: Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Recruiting
2
55
US
Atezolizumab, Tecentriq, Tocilizumab, Actemra, Tiragolumab, anti-TIGIT
Alain Algazi, Genentech, Inc.
Cancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer
06/27
06/27
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
NCT06043674: A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation

Recruiting
2
66
US
Glofitamab, RO7082859, Obinutuzumab, RO5072759, GA101, GAZYVA, GAZYVARO, Polatuzumab Vedotin, Atezolizumab, Tecentriq, Tocilizumab, Actemra
Christine Ryan, Genentech, Inc.
Chronic Lymphocytic Leukemia, Richter's Transformation
01/28
01/33
LCNEC-ALPINE, NCT05470595: A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung

Recruiting
2
67
Europe
Atezolizumab
Technische Universität Dresden, Roche Pharma AG
Large Cell Neuroendocrine Carcinoma of the Lung
01/28
01/29
SKYSCRAPER-05, NCT04832854: A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Calendar Jan 2025 - Dec 2025: Data from SKYSCRAPER-05 trial for NSCLC
Active, not recruiting
2
50
Europe, US, RoW
Atezolizumab, Tecentriq, Tiragolumab, MTIG7192A, Carboplatin, Cisplatin, Pemetrexed, Gemcitabine, Paclitaxel
Hoffmann-La Roche
Non-Small Cell Lung Cancer (NSCLC)
04/28
04/28
BOUQUET, NCT04931342 / 2020-004936-72: A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

Active, not recruiting
2
176
Europe, Canada, US, RoW
Ipatasertib, RO5532961, Cobimetinib, RO5514041, Trastuzumab Emtansine, RO5304020, Atezolizumab, RO5541267, Tecentriq, Bevacizumab, RO4876646, Avastin, Paclitaxel, Giredestrant, Abemaciclib, Inavolisib, Palbociclib, Letrozole, Olaparib, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, Cyclophosphamide
Hoffmann-La Roche, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Ovarian Cancer
05/28
12/28
NCT05935774: OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

Withdrawn
2
30
US
Atezolizumab, MPDL328OA, RG7446, RO5541267, Tecentriq, Biopsy, Bx, Biospecimen Collection, Biological Sample Collection, Computed Tomography, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Electronic Health Record Review, Magnetic Resonance Imaging, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Trabedersen (OT-101), AP 12009
University of Washington, Genentech, Inc., Oncotelic Therapeutics, Inc.
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
07/28
07/28
PERSEVERE, NCT04849364: Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

Recruiting
2
197
US
Capecitabine, Xeloda, Talazoparib, Talzenna, Pembrolizumab, Keytruda, Inavolisib, GDC-0077
Bryan Schneider, MD, Genentech, Inc., Pfizer, Foundation Medicine, Indiana University, Vera Bradley Foundation for Breast Cancer Research
Breast Cancer, Triple Negative Breast Cancer
01/29
01/34
IMCODE003, NCT05968326: A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected Pancreatic Ductal Adenocarcinoma

Recruiting
2
260
Europe, Canada, US
Autogene cevumeran, Atezolizumab, Tecentriq, mFOLFIRINOX
Genentech, Inc., BioNTech SE
Adenocarcinoma, Pancreatic Ductal
12/29
12/29
NCT00781612 / 2010-021067-32: A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Recruiting
2
720
Europe, Canada, Japan, US, RoW
Docetaxel, Paclitaxel, Pertuzumab, Perjeta, Trastuzumab, Herceptin, Trastuzumab Emtansine, Kadcyla; T-DM1, Atezolizumab, Tecentriq
Genentech, Inc., Hoffmann-La Roche
Neoplasm Metastasis
09/29
09/29
NCT05825625: NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing

Recruiting
2
35
Europe
Atezolizumab, Tecentriq, Tiragolumab, no other name available
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Thoraxklinik-Heidelberg gGmbH, Roche Pharma AG
Non-small Cell Lung Cancer
11/29
02/30
TAPISTRY, NCT04589845 / 2020-001847-16: Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You () Platform Study

Recruiting
2
920
Europe, Canada, Japan, US, RoW
Entrectinib, Rozlytrek, Alectinib, Alecensa, Atezolizumab, Tecentriq, Ipatasertib, Trastuzumab emtansine, Kadcyla, Idasanutlin, Inavolisib, GDC-0077, Belvarafenib, Pralsetinib, Gavreto (US), GDC-6036, Camonsertib
Hoffmann-La Roche
Solid Tumors
09/32
09/32
MANTRA-4, NCT06090318: Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Withdrawn
1b/2
NA
Milademetan, RAIN-32, Atezolizumab, TECENTRIQ
Rain Oncology Inc
Advanced Solid Tumor, CDKN2A, NSCLC, Urothelial Carcinoma Bladder, Melanoma, Pancreas Adenocarcinoma, HNSCC, Renal Cell Carcinoma, Mesothelioma, Gastric Cancer
05/23
05/23
2018-003172-12: A Phase 1/2, open-label, multi-center study of the safety and efficacy ofKY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies

Not yet recruiting
1/2
412
Europe
KY1044, Atezolizumab, KY1044, Concentrate for solution for infusion, Tecentriq
Kymab Ltd, Kymab Limited, Kymab Ltd
Advanced/metastatic malignancies, and preferred indications: head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), esophageal cancer, gastric cancer, melanoma, renal cell cancer, pancreatic cancer, cervical cancer, and triple negative breast cancer (BC), selected advanced malignancies, Diseases [C] - Cancer [C04]
 
 
2018-003120-36: An open-label study in patients with advanced cancer

Not yet recruiting
1/2
174
Europe
IMC-C103C, Atezolizumab, IMC-C103C, 1380723-44, Concentrate for solution for infusion, Tecentriq
Immunocore Limited, Immunocore Limited
Patients with metastatic/unresectable tumors of interest which include NSCLC, esophageal carcinoma, gastric carcinoma, HNSCC, urothelial carcinoma, ovarian carcinoma and synovial sarcoma, Patients with advanced non-small cell lung cancer, head and neck cancer, esophageal cancer, gastric, bladder cancer (also called urothelial cancer), ovarian cancer and synovial sarcoma, Diseases [C] - Cancer [C04]
 
 
2020-002770-27: First-in-human (FIH) study of DRP-104 as single agent and in combination with atezolizumab in patients with advanced solid tumors.

Not yet recruiting
1/2
170
Europe
DRP-104 for Intravenous Infusion, DRP-104 for Subcutaneous Administration, Tecentriq, Powder for concentrate for solution for infusion, Powder for solution for injection, Concentrate for solution for infusion, TECENTRIQ
Dracen Pharmaceuticals, Inc., Dracen Pharmaceuticals, Inc.
Cancer, advanced solid tumors, Cancer, Diseases [C] - Cancer [C04]
 
 
2021-000707-20: A Phase 1/2a study of AFM24 and Atezolizumab in patients with advanced and metastatic cancers Estudio de fase 1/2a de AFM24 y atezolizumab en pacientes con cáncer avanzado y metastásico

Not yet recruiting
1/2
165
Europe
AFM24, Tecentriq, Powder for solution for injection/infusion, Concentrate for solution for infusion, Tecentriq
Affimed GmbH, Affimed GmbH
Advanced/Metastatic EGFR-expressing Cancers Cáncer avanzado/metastásico que expresan EGFR, Advanced/Metastatic Cancers Cáncer avanzado/metastásico, Diseases [C] - Cancer [C04]
 
 
2021-002147-29: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients with Melanoma (Morpheus-Melanoma) Un estudio que evalúa la eficacia y seguridad de múltiples combinaciones de tratamientos en pacientes con melanoma (morfeo-melanoma)

Not yet recruiting
1/2
336
Europe
Atezolizumab, PD1-LAG3, OPDIVO, tiragolumab, ipilimumab, RO5541267, RO7247669, RO7344269, RO7092284, Concentrate for solution for infusion, Tecentriq, OPDIVO®, YERVOY 5 mg/ml concentrate for solution for infusion
Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Melanoma Melanoma, Melanoma is a form of skin cancer that begins in the cells (melanocytes) that control the pigment in your skin El melanoma es una forma de cáncer de piel que comienza en las células (melanocitos) que controlan el pigmento de la piel., Diseases [C] - Cancer [C04]
 
 
2021-005327-20: TEMPLE - A phase Ib/II study to determine the safety, tolerability andefficacy of Atezolizumab given in combination with thiopurine therapy inpatients with advanced and/or metastatic solid tumors

Not yet recruiting
1/2
39
Europe
Mercaptopurine, Tioguanine, Concentrate and solvent for solution for infusion, Tablet, Tecentriq, Mercaptopurine, Tioguanine
Rigshospitalet, Børnecancerfonden, Roche A/S
Metastatic or advanced solid tumors with an intermediate tumor mutational burden, Incurable solid cancers forms where the tumor is not hypermutated, Diseases [C] - Cancer [C04]
 
 
2020-002927-13: Atezolizumab treatment together with the BEGEV regimen in patients with resistant Hodgkin's lymphoma and candidates for autologous stem cell transplantation. Trattamento di atezolizumab associato a combinazione BEGEV in pazienti con linfoma di Hodgkin resistente e candidati al trapianto autologo di cellule staminali.

Not yet recruiting
1/2
140
Europe
Atezolizumab, Bendamustina, Gemcitabina, Vinorelbina, [IMP2], [IMP3], [IMP4], [IMP5], [IMP6], [IMP1], Concentrate for solution for infusion, Powder for concentrate for solution for infusion, TECENTRIQ - 840 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 20 ML (60 MG/ML) - 1 FLACONCINO, BENDAMUSTINA ACCORD - 2,5 MG/ML POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - 5 FLACONCINI DA 40 ML, BENDAMUSTINA ACCORD - 2,5 MG/ML POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - 5 FLACONCINI DA 10 ML, Gemcitabina cloridrato, VINORELBINA ACTAVIS - 10 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO DI VETRO DA 5 ML, TECENTRIQ - 1200 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 20 ML (60 MG/ML) - 1 FLACONCINO
FONDAZIONE ITALIANA LINFOMI ONLUS, Roche S.p.A.
Refractory/relapsed Hodgkin Lymphoma. Linfoma di Hodgkin ricaduto/refrattario., Refractory/relapsed Hodgkin Lymphoma. Linfoma di Hodgkin ricaduto/refrattario., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2021-004155-16: Phase Ib study investigating dose, safety and efficacy of [177Lu]Lu-DOTA-TATE in patients with Extensive Stage Small Cell Lung Cancer (specific form of lung tumour)

Not yet recruiting
1/2
200
Europe
Tislelizumab, Solution for infusion, Kit for radiopharmaceutical preparation, Concentrate for solution for infusion, Lutathera, NETSPOT, Baize’an
Novartis Pharma AG, Novartis Pharma AG
Extensive-Stage Small Cell Lung Cancer, Specific form of lung tumour, Diseases [C] - Cancer [C04]
 
 
VENEZO-LUNG, NCT04487756: Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer

Active, not recruiting
1/2
20
Europe
Atezolizumab 1200 mg in 20 ML Injection, Tecentriq, ADC Vaccine, Autologous Dendritic cell (ADC) vaccine, Dendritic cell (DC) vaccine, Carboplatin, Carboplatino (Teva/Accord/Pharmacia)
Instituto Oncológico Dr Rosell, Roche Pharma AG, Fundacion Clinic per a la Recerca Biomédica
Extensive-stage Small Cell Lung Cancer
08/24
10/24
2021-003229-31: Integration of immunotherapy into first-line chemotherapy voor patients with epithelioid malignant pleural mesothelioma Toevoeging van immuuntherapie aan de eerstelijnschemotherapie voor patiënten met epitheliale longvlieskanker

Not yet recruiting
1/2
15
Europe
cryopreserved Wilms' tumor 1 (WT1) mRNA-electroporated dendritic cells, WT1/DC, Suspension for injection, Concentrate for solution for infusion, Tecentriq
Antwerp University Hospital, Kom op tegen Kanker, NV Roche SA
Malignant pleural mesothelioma, epithelioid subtype (stage I-IV) Maligne pleuraal mesothelioma, epithelioïde subtype (stadium I-IV), Asbestos cancer Asbestkanker (longvlieskanker), Diseases [C] - Cancer [C04]
 
 
 

Download Options